Investigating the pharmacological and nonpharmacological factors that modulate drug reinforcement

Experimental and Clinical Psychopharmacology

Volumn 15, Issue 1, 2007, Pages 1-20

  Sigmon, Stacey C ^a,b  

^a UNIVERSITY OF VERMONT   (United States)

^b FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

Behavioral interventions; Contingency management; Drug abstinence; Drug abuse; Pharmacotherapy; Reinforcement

Indexed keywords

AMPHETAMINE; BUPRENORPHINE; CAFFEINE; CANNABIS; CENTRAL STIMULANT AGENT; COCAINE; DEXAMPHETAMINE; HYDROMORPHONE; ILLICIT DRUG; METHADONE; METHYLPHENIDATE; NICOTINE; OPIATE; PLACEBO;

ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CIGARETTE SMOKING; DRUG ABUSE; DRUG DEPENDENCE; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG TARGETING; DRUG TOLERANCE; DRUG WITHDRAWAL; HUMAN; REINFORCEMENT; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SINGLE DRUG DOSE; WITHDRAWAL SYNDROME;

BEHAVIORAL RESEARCH; HUMANS; PSYCHOPHARMACOLOGY; RISK FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 33846999905     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/1064-1297.15.1.1     Document Type: Review

References (113)

1. Ahmadi, J. (2002). A controlled trial of buprenorphine treatment for opium dependence: The first experience from Iran. Drug and Alcohol Dependence, 66, 111-114.
2. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
3. Ball, J. C., & Ross, A. (1991). The effectiveness of methadone maintenance treatment. New York: Springer-Verlag.
4. Bellack, A. S., & Gearon, J. S. (1998). Substance abuse treatment for people with schizophrenia. Addictive Behaviors, 23, 749-766.
5. Benowitz, N. L. (1998). Summary: Risks and benefits of nicotine. In N. L. Benowitz (Ed.), Nicotine safety and toxicity (pp. 185-194). New York: Oxford University Press.
6. Bickel, W. K., Stitzer, M. L., Bigelow, G. E., Liebson, I. A., Jasinski, D. R., & Johnson, R. E. (1988a). Buprenorphine: Dose-related blockade of opioid challenge effects in opioid dependent humans. Journal of Pharmacology and Experimental Therapeutics, 247, 47-53.
7. Bickel, W. K., Stitzer, M. L., Bigelow, G. E., Liebson, I. A., Jasinski, D. R., & Johnson, R. E. (1988b). A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clinical Pharmacology and Therapeutics, 43, 72-78.
8. Biederman, J., Wilen, T., Mick, E., Spencer, T., & Faraone, S. V. (1999). Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk of substance use disorder. Pediatrics, 104, e20.
9. Bigelow, G. E., Sobel, B.-F. X., Terry, A. J., & Liebson, E. A. (2001, May). Clinical evaluation of depot naltrexone. Paper presented at the European Workshop: Alcohol and Drugs of Abuse, Brussels, Belgium.
10. Budney, A. J., Higgins, S. T., Hughes, J. R., & Bickel, W. K. (1993). Nicotine and caffeine use in cocaine-dependent individuals. Journal of Substance Abuse, 5, 117-130.
11. Bullingham, R. E. S., McQuay, H. J., Moore, A., & Bennett, M. R. D. (1980). Buprenorphine kinetics. Clinical Pharmacology & Therapeutics, 28, 667-672.
12. Carey, M. P., Carey, K. B., Weinhardt, L. S., & Gordon, C. M. (1997). Behavioral risk for HIV infection among adults with a severe and persistent mental illness: Patterns and psychological antecedents. Community Mental Health Journal, 33, 133-142.
13. Chait, L. D., & Griffiths, R. R. (1983). Effects of caffeine on cigarette smoking and subjective response. Clinical Pharmacology & Therapeutics, 34, 612-622.
14. Chait, L. D., & Griffiths, R. R. (1984). Effects of methadone on human cigarette smoking and subjective ratings. Journal of Pharmacology and Experimental Therapeutics, 229, 636-640.
15. Challman, T. D., & Lipsky, J. J. (2000). Methylphenidate: Its pharmacology and uses. Mayo Clinic Proceedings, 75, 711-721.
16. Clemmey, P., Brooner, R., Chutuape, M. A., Kidorf, M., & Stitzer, M. (1997). Smoking habits and attitudes in a methadone maintenance treatment population. Drug and Alcohol Dependence, 44, 123-132.
17. Correia, C. J., Sigmon, S. C., Silverman, K., Bigelow, G., & Stitzer, M. L. (2005). A comparison of voucher delivery schedules for the initiation of cocaine abstinence. Experimental and Clinical Psychopharmacology, 13, 253-258.
18. Cousins, M. S., Stamat, H. M., & de Wit, H. (2001). Acute doses of d-amphetamine and buproprion increase cigarette smoking. Psychopharmacology, 157, 243-253.
19. de Villiers, P. (1977). Choice in concurrent schedules and a quantitative formulation of the law of effect. In W. K. Honig & J. E. R. Staddon (Eds.), Handbook of operant behavior (pp. 233-287). Englewood Cliffs, NJ: Prentice-Hall.
20. Diamant, K., Fischer, G., Schneider, C., Lenzinger, E., Pezawas, L., Schindler, S., & Eder, H. (1998). Outpatient opiate detoxification treatment with buprenorphine: Preliminary investigation. European Addiction Research, 4, 198-202.
21. Di Chiara, G. (2000). Role of dopamine in the behavioural actions of nicotine related to addiction. European Journal of Pharmacology, 393, 295-314.
22. Drake, R. E., Wallach, M. A., Teague, G. B., Freeman, D. H., Paskus, T. S., & Clark, T. A. (1991). Housing instability and homelessness among rural schizophrenic patients. American Journal of Psychiatry, 148, 330-336.
23. Dunn, K., Sigmon, S. C., & Higgins, S. T. (2006). Incentive-based smoking cessation for methadone patients: A feasibility study. Manuscript in progress.
24. Eissenberg, T., Greenwald, M. K., Johnson, R. E., Liebson, I. A., Bigelow, G. E., & Stitzer, M. L. (1996). Buprenorphine's physical dependence potential: Antagonist-precipitated withdrawal in humans. Journal of Pharmacology and Experimental Therapeutics, 276, 449-459.
25. Engstrom, A., Adamsson, C., Allebeck, P., & Rydberg, U. (1991). Mortality in patients with substance abuse: A follow-up in Stockholm County, 1973-84. International Journal of Addictions, 26, 91-106.
26. Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999). Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacological Reviews, 51, 83-133.
27. Frosch, D. L., Nahom, D., & Shoptaw, S. (2002). Optimizing smoking cessation among the methadone maintained. Journal of Substance Abuse Treatment, 23, 425-430.
28. Fudala, P. J., Jaffe, J. H., Dax, E. M., & Johnson, R. E. (1990). Use of buprenorphine in the treatment of opiate addiction: II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clinical Pharmacology & Therapeutics, 47, 525-534.
29. Garrett, B. E., & Griffiths, R. R. (1997). The role of dopamine in the behavioral effects of caffeine in animals and humans. Pharmacology, Biochemistry and Behavior, 57, 533-541.
30. Griffiths, R. R., Rush, C. R., & Puhala, K. A. (1996). Validation of the multiple-choice procedure for investigating drug reinforcement in humans. Experimental and Clinical Psychopharmacology, 4, 97-106.
31. Griffiths, R. R., Troisi, J. R., Silverman, K., & Mumford, G. K. (1993). Multiple-choice procedure: An efficient approach for investigating drug reinforcement in humans. Behavioural Pharmacology, 4, 3-13.
32. Hambrook, J. M., & Rance, M. J. (1976). The interaction of buprenorphine with the opiate receptor: Lipophilicity as a determining factor in drug-receptor kinetics. In H. W. Kosterlitz (Ed.), Opiates and endogenous opioid peptides (pp. 295-301). Amsterdam: Elsevier/North Holland, Biomedical Press.
33. Heishman, S. J., & Henningfield, J. E. (2000). Tolerance to repeated nicotine administration on performance, subjective, and physiological responses in nonsmokers. Psychopharmacology, 152, 321-333.
34. Henningfield, J. E. (1984). Behavioral pharmacology of cigarette smoking. In T. Thompson, P. B. Dews, & J. E. Barrett (Eds.), Advances in behavioral pharmacology (pp. 131-210). Orlando, FL: Academic Press.
35. Henningfield, J. E., Clayton, R., & Pollin, W. (1990). Involvement of tobacco in alcoholism and illicit drug use. British Journal of Addiction, 85, 279-292.
36. Henningfield, J. E., & Griffiths, R. R. (1981). Cigarette smoking and subjective response: Effects of d-amphetamine. Clinical Pharmacology & Therapeutics, 30, 497-505.
37. Higgins, S. T., Alessi, S. M., & Dantona, R. L. (2002). Voucher-based incentives: A substance abuse treatment innovation. Addictive Behaviors, 27, 887-910.
38. Higgins, S. T., Budney, A. J., Hughes, J. R., Bickel, W. K., Lynn, M., & Mortensen, A. (1994). Influence of cocaine use on cigarette smoking. Journal of the American Medical Association, 272, 1724.
39. Higgins, S. T., Delaney, D. D., Budney, A. J., Bickel, W. K., Hughes, J. R., Foerg, F., & Fenwick, J. W. (1991). A behavioral approach to achieving initial cocaine abstinence. American Journal of Psychiatry, 148, 1218-1224.
40. Higgins, S. T., Heil, S. H., Dumeer, A. M., Thomas, C. S., Solomon, L. J., & Bernstein, I. M. (2006). Smoking status in the initial weeks of quitting as a predictor of smoking-cessation outcomes in pregnant women. Drug and Alcohol Dependence, 85, 138-141.
41. Higgins, S. T., Heil, S. H., & Lussier, J. P. (2004). Clinical implications of reinforcement as a determinant of substance use disorders. Annual Review of Psychology, 55, 431-461.
42. Higgins, S. T., Sigmon, S. C., Wong, C. J., Heil, S. H., Badger, G. J., Donham, R., et al. (2003). Community reinforcement therapy for cocaine-dependent outpatients. Archives of General Psychiatry, 60, 1043-1052.
43. Higgins, S. T., & Silverman, K. (1999). Motivating behavior change among illicit-drug abusers. Washington, DC: American Psychological Association.
44. Higgins, S. T., Wong, C. J., Badger, G. J., Haug Ogden, D. E., & Dantona, R. L. (2000). Contingent reinforcement increases cocaine abstinence during outpatient treatment and 1 year of follow-up. Journal of Consulting and Clinical Psychology, 68, 64-72.
45. Himmelsbach, C. K. (1941). The morphine abstinence syndrome, its nature and treatment. Annals of Internal Medicine, 15, 829-839.
46. Hodos, W. (1961, September 29). Progressive ratio as a measure of reward strength. Science, 134, 943-944.
47. Hodos, W., & Kalman, G. (1963). Effects of increment size and reinforcer volume on progressive ratio performance. Journal of the Experimental Analysis of Behavior, 6, 387-392.
48. Hser, Y. I., McCarthy, W. J., & Anglin, M. D. (1994). Tobacco use as a distal predictor of mortality among long-term narcotic addicts. Preventive Medicine, 23, 61-69.
49. Istvan, J., & Matarazzo, J. D. (1984). Tobacco, alcohol, and caffeine use: A review of their interrelationships. Psychological Bulletin, 95, 301-326.
50. Jasinski, D. R., Pevnick, J. S., & Griffith, J. D. (1978). Human pharmacology and abuse potential of the analgesic buprenorphine. Archives of General Psychiatry, 35, 501-516.
51. Johnson, R. E., Jaffe, J. H., & Fudala, P. J. (1992). A controlled trial of buprenorphine treatment for opioid dependence. Journal of the American Medical Association, 267, 2750-2755.
52. Jones, H. E., & Griffiths, R. R. (2003). Oral caffeine maintenance potentiates the reinforcing and stimulant subjective effects of intravenous nicotine in cigarette smokers. Psychopharmacology, 165, 280-290.
53. Kandel, D. B., Chen, K., Warner, L., Kessler, R., & Grant, B. (1997). Prevalence and demographic correlates of symptoms of dependence on cigarettes, alcohol, marijuana and cocaine in the U.S. population. Drug and Alcohol Dependence, 44, 11-29.
54. Kelleher, R. T., & Morse, W. H. (1968). Determinants of the specificity of behavioral effects of drugs. Reviews of Physiology, Biochemistry, and Experimental Pharmacology, 60, 1-56.
55. Kenford, S. L., Fiore, M. C., Jorenby, D. E., Smith, S. S., Wetter, D., & Baker, T. B. (1994). Predicting smoking cessation: Who will quit with and without the nicotine patch. Journal of the American Medical Association, 271, 589-594.
56. Koob, G. F., & Nestler, E. J. (1997). The neurobiology of drug addiction. Journal of Neuropsychiatry and Clinical Neurosciences, 9, 482-497.
57. Kosten, T. R., & Kleber, H. D. (1988). Buprenorphine detoxification from opioid dependence: A pilot study. Life Sciences, 42, 635-641.
58. Lewis, J. W. (1985). Buprenorphine. Drug and Alcohol Dependence, 14, 363-372.
59. Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., et al. (1998). Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction, 93, 475-486.
60. Lintzeris, N., Bell, J., Bammer, G., Jolley, D. J., & Rushworth, L. (2002). A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction, 97, 1395-1404.
61. Mazur, J. E. (1994). Choice. In J. E. Mazur (Ed.), Learning and behavior (3rd ed., pp. 334-365). Englewood Cliffs, NJ: Prentice-Hall.
62. Mello, N. K., Mendelson, J. H. (1980, February 8). Buprenorphine suppresses heroin use by heroin addicts. Science, 207, 657-659.
63. Mello, N. K., & Mendelson, J. H. (1986). Cigarette smoking: Interactions with alcohol, opiates and marijuana. In M. C. Braud & H. L. Ginzburg (Eds.), Strategies for research on the interactions of drugs of abuse (pp. 154-180) [Monograph]. Washington, DC: U.S. Government Printing Office.
64. Mello, N. K., Mendelson, J. H., & Kuehnle, J. C. (1982). Buprenorphine effects on heroin self-administration: An operant analysis. Journal of Pharmacology and Experimental Therapeutics, 223, 30-39.
65. Minor, R. L., Scott, B. D., Brown, D. D., & Winniford, M. D. (1991). Cocaine-induced myocardial infarction in patients with normal coronary arteries. Annals of Internal Medicine, 115, 797-806.
66. Moliterno, D. J., Willard, J. E., Lange, R. A., Negus, B. H., Boehrer, J. D., Glamann, D. B., et al. (1994). Coronary-artery vasoconstriction induced by cocaine, cigarette smoking, or both. New England Journal of Medicine, 330, 454-459.
67. Mueser, K. T., Yarnold, P. R., Levinson, D. F., Singh, H., Bellack, A. S., Kee, K., et al. (1990). Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates. Schizophrenia Bulletin, 16, 31-54.
68. National Institute on Drug Abuse. (2001). NIDA research report: Nicotine addiction (NIH Publication No. 01-4342). Rockville, MD: Author.
69. Negrete, J. C., & Gill, K. (1999). Cannabis and schizophrenia: An overview of the evidence to date. In G. G. Nahas (Ed.), Marihuana and medicine (pp. 671-681). Totowa, NJ: Humana Press.
70. Nemeth-Coslett, R., Henningfield, J. E., Katz, J., & Goldberg, S. (1986). Effect of cocaine on rate of cigarette smoking. Pharmacology, Biochemistry and Behavior, 25, 303.
71. Peniston, E. G. (1988). Evaluation of long-term therapeutic efficacy of behavior modification program with chronic male psychiatric inpatients. Journal of Behavior Therapy and Experimental Psychiatry, 19, 95-101.
72. Perkins, K. A. (2002). Chronic tolerance to nicotine in humans and its relationship to tobacco dependence. Nicotine and Tobacco Research, 4, 405-422.
73. Perkins, K. A., Grobe, J. E., Epstein, L. H., Caggiula, A., Stiller, R. L., & Jacob, R. G. (1993). Chronic and acute tolerance to subjective effects of nicotine. Pharmacology, Biochemistry and Behavior, 45, 375-381.
74. Perkins, K. A., Grobe, J. E., Fonte, C., Goettler, J., Caggiula, A. R., Reynolds, W. A., et al. (1994). Chronic and acute tolerance to subjective, behavioral, and cardiovascular effects of nicotine in humans. Journal of Pharmacology and Experimental Therapeutics, 270, 628-638.
75. Preston, K. L., Bigelow, G. E., & Liebson, I. A. (1988). Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology, 94, 484-490.
76. Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., & Goodwin, F. K. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Journal of the American Medical Association, 264, 2511-2518.
77. Richter, K. P., Gibson, C. A., Ahluwalia, J. S., & Schmelzle, K. H. (2001). Tobacco use and quit attempts among methadone maintenance clients. American Journal of Public Health, 91, 296-299.
78. Roll, J. M., & Higgins, S. T. (2000). A within-subject comparison of three different schedules of reinforcement of drug abstinence using cigarette smoking as an exemplar. Drug and Alcohol Dependence, 58, 103-109.
79. Roll, J. M., Higgins, S. T., Budney, A. J., Bickel, W. K., & Badger, G. J. (1996). A comparison of cocaine-dependent cigarette smokers on demographics, drug use and other characteristics. Drug and Alcohol Dependence, 40, 195-201.
80. Roll, J. M., Higgins, S. T., Steingard, S., & McGinley, M. (1998). Use of monetary reinforcement to reduce the cigarette smoking of persons with schizophrenia: A feasibility study. Experimental and Clinical Psychopharmacology, 6, 147-161.
81. Roll, J. M., Higgins, S. T., & Tidey, J. W. (1997). Cocaine use can increase cigarette smoking: Evidence from laboratory and naturalistic settings. Experimental and Clinical Psychopharmacology, 5, 263-268.
82. Rosen, M. I., Wallace, E. A., McMahon, T. J., Pearsall, R., Woods, S. W., Price, L. H., & Kosten, T. R. (1994). Buprenorphine: Duration of blockade of effects of intramuscular hydromorphone. Drug and Alcohol Dependence, 35, 141-149.
83. Rush, C. R., Higgins, S. T., Vansickel, A. R., Stoops, W. W., Lile, J. A., & Glaser, P. E. (2005). Methylphenidate increases cigarette smoking. Psychopharmacology, 181, 781-789.
84. Schmitz, J. M., Grabowski, J., & Rhoades, H. (1994). The effects of high and low doses of methadone on cigarette smoking. Drug and Alcohol Dependence, 34, 237-242.
85. Schottenfeld, R. S., Pakes, J. R., Oliveto, A., Ziedonis, D., & Kosten, T. R. (1997). Buprenorphine versus methadone maintenance for concurrent opiate dependence and cocaine abuse. Archives of General Psychiatry, 54, 713-720.
86. Schuh, K. J., & Griffiths, R. R. (1997). Caffeine reinforcement: The role of withdrawal. Psychopharmacology, 130, 320-326.
87. Schuster, C. R., Lucchesi, B. R., & Emley, G. S. (1979). The effects of d-amphetamine, meprobamate, and lobeline on the cigarette smoking behavior of normal human subjects. In N. Krasnegor (Ed.), Cigarette smoking as a dependence process (pp. 91-99) [Monograph]. Washington, DC: U.S. Government Printing Office.
88. Shaner, A., Roberts, L. J., Eckman, T. A., Tucker, D. E., Tsuang, J. W., Wilkins, J. N., & Mintz, J. (1997). Monetary reinforcement of abstinence from cocaine among mentally ill patients with cocaine dependence. Psychiatric Services, 48, 807-810.
89. Shoptaw, S., Jarvik, M. E., Ling, W., & Rawson, R. A. (1996). Contingency management for tobacco smoking in methadone-maintained opiate addicts. Addictive Behaviors, 21, 409-412.
90. Shoptaw, S., Rotheram-Fuller, E., Yang, X., Frosch, D., Nahom, D., Jarvik, M. E., et al. (2002). Smoking cessation in methadone maintenance. Addiction, 97, 1317-1328.
91. Sigmon, S. C., Correia, C., & Stitzer, M. L. (2004). Cocaine abstinence during methadone maintenance: Effects of repeated exposure to voucher-based reinforcement and predictive utility for response to abstinence incentive interventions. Experimental and Clinical Psychopharmacology, 12, 269-275.
92. Sigmon, S. C., & Higgins, S. T. (2006). Voucher-based contingent reinforcement of marijuana abstinence among individuals with serious mental illness. Journal of Substance Abuse Treatment, 30, 291-295.
93. Sigmon, S. C., Steingard, S., Badger, G. J., Anthony, S. L., & Higgins, S. T. (2000). Contingent reinforcement of marijuana abstinence among individuals with serious mental illness: A feasibility study. Experimental and Clinical Psychopharmacology, 8, 509-517.
94. Sigmon, S. C., Tidey, J. W., Badger, G. J., & Higgins, S. T. (2003). Acute effects of d-amphetamine on progressive-ratio performance maintained by cigarette smoking and money. Psychopharmacology, 167, 393-402.
95. Sigmon, S. C., Wong, C. J., Nuwayser, E., Chausmer, A., & Bigelow, G. E. (2004). Evaluation of depot buprenorphine: Placebo comparison. Addiction, 99, 1439-1449.
96. Silverman, K., Higgins, S. T., Brooner, R. K., Montoya, I. D., Cone, E. J., Schuster, C. R., & Preston, K. L. (1996). Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Archives of General Psychiatry, 53, 409-415.
97. Smith, B. J., Jones, H. E., & Griffiths, R. R. (2001). Physiological, subjective and reinforcing effects of oral and intravenous cocaine in humans. Psychopharmacology, 156, 435-444.
98. Sobel, B.-F. X., Sigmon, S. C., & Griffiths, R. R. (2004). Nicotine maintenance attenuates the subjective and reinforcing effects of intravenous nicotine, but not cocaine or caffeine, in cigarette-smoking stimulant abusers. Neuropsychopharmacology, 29, 991-1003.
99. Sobel, B.-F. X., Sigmon, S. C., Walsh, S. L., Johnson, R. E., Liebson, I. A., Nuwayser, E. S., et al. (2004). Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug and Alcohol Dependence, 73, 11-22.
100. Stark, M. J., & Campbell, B. K. (1993). Cigarette smoking and methadone dose levels. American Journal of Drug and Alcohol Abuse, 19, 209-217.
101. Stitzer, M. L., & Sigmon, S. C. (2006). Other substance use disorders: Prevalence, consequences, detection and management. In E. C. Strain & M. L. Stitzer (Eds.), The treatment of opioid dependence (pp. 365-397). Baltimore: Johns Hopkins University Press.
102. Strain, E. C., Stitzer, M. L., Liebson, I. A., & Bigelow, G. E. (1994). Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry, 151, 1025-1030.
103. Substance Abuse and Mental Health Services Administration. (2003). Results from the 2002 National Survey on Drug Use and Health: National findings (NHSDA Series H-22, DHHS Publication No. SMA 03-3836). Rockville, MD: Department of Health and Human Services, Office of Applied Studies.
104. Swanson, J. A., Lee, J. W., & Hopp, J. W. (1994). Caffeine and nicotine: A review of their joint use and possible interactive effects in tobacco withdrawal. Addictive Behaviors, 19, 229-256.
105. Tanda, G., & Goldberg, S. R. (2000). Alteration of the behavioral effects of nicotine by chronic caffeine exposure. Pharmacology, Biochemistry and Behavior, 66, 47-64.
106. Tidey, J. W., O'Neill, S. C., & Higgins, S. T. (2000). d-Amphetamine increases choice of cigarette smoking over monetary reinforcement. Psychopharmacology, 153, 85-92.
107. Walsh, S. L., Preston, K. L., Bigelow, G. E., & Stitzer, M. L. (1995). Acute administration of buprenorphine in humans: Partial agonist and blockade effects. Journal of Pharmacology and Experimental Therapeutics, 274, 361-372.
108. Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994). Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology & Therapeutics, 55, 569-580.
109. West, R. J., & Russell, M. A. H. (1987). Cardiovascular and subjective effects of smoking before and after 24 h of abstinence from cigarettes. Psychopharmacology, 92, 118-121.
110. Wiseman, E. J., & McMillan, D. E. (1996). Combined use of cocaine with alcohol or cigarettes. American Journal of Drug and Alcohol Abuse, 22, 577-587.
111. Zernig, G., O'Laughlin, I. A., & Fibiger, H. C. (1997). Nicotine and heroin augment cocaine-induced dopamine overflow in nucleus accumbens. European Journal of Pharmacology, 337, 1-10.
112. Zisook, S., Heaton, R., Moranville, J., Kuck, J., Jernigan, T., & Braff, D. (1992). Past substance abuse and clinical course of schizophrenia. American Journal of Psychiatry, 149, 552-553.
113. Zito, J. M., Safer, D. J., dosReis, S., Gardner, J. F., Boles, M., & Lynch, F. (2000). Trends in the prescribing of psychotropic medications to preschoolers. Journal of the American Medical Association, 283, 1025-1030.